Abstracts tagged "Psoriatic arthritis"

Abstract Number: 1753 • ACR Convergence 2025
Axial Psoriatic Arthritis is Phenocopied in a Humanized Mouse Model
Christopher Ritchlin¹, Javier Rangel-Moreno², Angel Rangel-Garcia³, Marissa Krantz⁴, Madison Brien², Thiloginy Sathilaseenlan², Jeffrey Fox⁵, Ronald Wood² and Maria de la Luz Garcia-Hernandez³, ¹University of Rochester Medical Center, Canandaigua, NY, ²University of Rochester, Rochester, NY, ³University of Rochester, West Henrietta, NY, ⁴University of Rochester, Bethesda, MD, ⁵University od Rochester, Rochester, NY
Background/Purpose: Psoriatic arthritis (PsA) is a complex and heterogeneous inflammatory disorder involving the axial skeleton in approximately 30% of patients. The mechanisms that underlie psoriatic…
Abstract Number: 1454 • ACR Convergence 2025
Long-Term Safety and Tolerability of Bimekizumab Treatment Across Phase 2b and Phase 3 Studies in Patients with Axial Spondyloarthritis or Psoriatic Arthritis: 3-Year Update from the Phase 3 Studies
Philip J. Mease¹, Denis Poddubnyy², Rajan Bajracharya³, Barbara Ink³, Myriam Manente⁴, Luke Peterson⁵, Katy White⁶, Peter Nash⁷ and Lianne S. Gensler⁸, ¹Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ²Division of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada, and Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany; Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany, ³UCB, Slough, England, United Kingdom, ⁴UCB, Braine-L'Alleud, Belgium, ⁵UCB, Morrisville, NC, ⁶UCB, Slough, United Kingdom, ⁷School of Medicine, Griffith University, Brisbane, Australia, ⁸Department of Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA

Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A. Previous analyses of phase (Ph)2b/3 safety data (data…
Abstract Number: 1414 • ACR Convergence 2025
Multidimensional Assessment to Differentiate Early Psoriatic Arthritis from Cutaneous Psoriasis
Eugeniu Russu¹, Victor Cazac², Mircea Betiu³, Alesea Nistor³ and Liliana Groppa⁴, ¹"Nicolae Testemitanu" State Medical and Pharmaceutical University; ”Timofei Moșneaga” Republican Clinical Hospital, Chisinau, Moldova, ²Norwalk Hospital, Nuvance Health, Connecticut, ³State Medical and Pharmaceutical University ”Nicolae Testemițanu”, Chisinau, Chisinau, Moldova, ⁴State Medical and Pharmaceutical University ”Nicolae Testemițanu”, Chisinau, Moldova
Background/Purpose: Psoriatic arthritis (PsA) develops in ~20-30% of psoriasis patients. However, early PsA diagnosis is challenging due to heterogeneous, subtle symptoms and overlap with psoriasis…
Abstract Number: 0591 • ACR Convergence 2025
An Interim Analysis of Health-Related Quality of Life Outcomes from an International Multicentre Observational Study in Patients with Psoriatic Arthritis Initiating Bimekizumab in Real-World Clinical Practice
Xenofon Baraliakos¹, Uta Kiltz¹, Kurt de Vlam², Adeline Ruyssen-Witrand³, Felipe Julio Ramirez Garcia⁴, Jessica A. Walsh⁵, Denis Poddubnyy⁶, David Nicholls⁷, Marga Oortgiesen⁸, Francesca Maria Ester Castagna⁹, Marie-Alix Bonny¹⁰, Hervé Besson¹¹, Jérémy Lambert¹², Rajan Bajracharya¹³, Patrik Öhagen¹⁴ and William Tillett¹⁵, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ²Department of Rheumatology, UZ Leuven, Leuven, Belgium, ³CHU of Toulouse - Pierre-Paul Riquet Hospital (Inflammation, Infection, Immunology and Locomotor Center - Rheumatology Service, Toulouse, France, ⁴Rheumatology Department, Hospital Clinic and IDIBAPS of Barcelona, Barcelona, Spain, ⁵Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, ⁶Division of Rheumatology, Department of Medicine, University Health Network and University of Toronto, Toronto, Ontario, Canada, and Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany; Department of Epidemiology, German Rheumatism Research Centre, Berlin, Germany, ⁷Clinical Trials Unit, University of the Sunshine Coast, Queensland, Australia, ⁸UCB, Raleigh, NC, ⁹UCB SpA, Milano, Italy, ¹⁰UCB, Brussels, Belgium, ¹¹UCB, Breda, Netherlands, ¹²UCB, Colombes, France, ¹³UCB, Slough, England, United Kingdom, ¹⁴UCB, Stockholm, Sweden, ¹⁵Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath, United Kingdom
Background/Purpose: PsA is a chronic inflammatory disease with a significant burden on patients’ (pts) health-related quality of life (HRQoL).1 Bimekizumab (BKZ), a monoclonal IgG1 antibody…
Abstract Number: 0559 • ACR Convergence 2025
Impact of Secukinumab on Cardiovascular Disease in Patients with Psoriasis, PsA, and Axial Spondyloarthritis: A Systematic Review of Existing Evidence
Javier R Godo¹, Christopher EM Griffiths², Miguel A. González-Gay³, Andreas Clemens⁴, Cynthia Vizcaya⁴, Lara Gómez⁵ and Nehal N Mehta⁶, ¹Department of Rheumatology and Joint and Bone Research Unit, Hospital Universitario Fundación Jiménez Díaz, and Instituto de Investigación Sanitaria-Fundación Jiménez Díaz, Madrid, Spain, ²Centre for Dermatology Research, Manchester Academic Health Science Centre, The University of Manchester, Manchester, UK and Department of Dermatology, King's College Hospital NHS Foundation Trust, King's College London, London, United Kingdom, ³Department of Rheumatology and Joint and Bone Research Unit, Hospital Universitario Fundación Jiménez Díaz, and Instituto de Investigación Sanitaria-Fundación Jiménez Díaz, Madrid, Spain, and Medicine and Psychiatry Department, University of Cantabria, Santander, Spain, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵Novartis Farmaceutica, Madrid, Spain, ⁶The George Washington University School of Medicine and Health Sciences, Washington DC
Background/Purpose: Psoriasis, psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) are associated with increased risk of cardiovascular (CV) disease driven by chronic systemic inflammation, with IL-17A…
Abstract Number: 0532 • ACR Convergence 2025
Generative artificial intelligence provides synthetic data to discriminate patients with seronegative rheumatoid arthritis versus psoriatic arthritis sine psoriasis
Antonio Tonutti¹, Saverio D'Amico², Pierandrea Morandini², Cosimo Faeti², Elisa Barone¹, Nicoletta Luciano¹, Victor Savevski² and Carlo Selmi³, ¹Humanitas University, Pieve Emanuele, Italy, ²IRCCS Humanitas Research Hospital, Rozzano, Italy, ³Humanitas University, Milan, Italy
Background/Purpose: Distinguishing seronegative rheumatoid arthritis (RA) from psoriatic arthritis (PsA) sine psoriasis remains challenging, often relying on pathognomonic features (axial involvement, enthesitis) present in only…
Abstract Number: 0267 • ACR Convergence 2025
Pharmacosurvellience study of FDA Adverse Event Reporting System (FAERS) events of Secukinumab and Guselkumab
NUR BARLAS¹, Sait Barlas¹ and Emre Adalier², ¹Florida State University College of Medicine, Cape Coral, ²University of Pavia School of Medicine & Surgery, Pavia, Italy
Background/Purpose: Interleukin-17 (IL-17) and interleukin-23 (IL-23) inhibitors have revolutionized treatment for psoriatic arthritis, axial spondyloarthritis, and moderate-to-severe plaque psoriasis. IL-17 inhibitors block the pro-inflammatory cytokine…
Abstract Number: 2371 • ACR Convergence 2025
A Predictive Model Combining Clinical and Laboratory Parameters to Predict anti-TNF Response in Patients with Psoriatic Arthritis
Raquel Granados¹, Jesús Eduardo Martín Salazar², María Ángeles Puche-Larrubia³, Pedro Ortiz Buitrago⁴, María Dolores López-Montilla⁵, Jerusalén Calvo⁶, Rafaela Ortega-Castro⁷, Montserrat Romero-Gómez⁸, Alejandro Escudero-Contreras⁹, Nuria Barbarroja¹⁰ and Clementina López Medina¹¹, ¹Hospital Universitario Reina Sofia, Cordoba, Andalucia, Spain, ²Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba/ Reina Sofia University Hospital, Rheumatology service/Department of Medical and Surgical Sciences, Cordoba, Spain, Cordoba, Andalucia, Spain, ³Reina Sofia University Hospital, Granada, Spain, ⁴Maimonides Institute of Biomedical Research of Córdoba (IMIBIC), Cordoba, Andalucia, Spain, ⁵Rheumatology Department, Reina Sofía University Hospital, Cordoba/IMIBIC/University of Cordoba., CORDOBA, Spain, ⁶IMIBIC / Reina Sofia Hospital / University of Cordoba, Córdoba, Spain, ⁷Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain, Cordoba, Andalucia, Spain, ⁸Reina Sofia University Hospital, Cordoba, Andalucia, Spain, ⁹Reina Sofia University Hospital/Maimonides Institute of Biomedical Research of Córdoba(IMIBIC)/University of Cordoba, Cordoba, Andalucia, Spain, ¹⁰Rheumatology service/Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ Reina Sofia University Hospital/ University of Cordoba, Spain/CobiomicBioscience S.l, Cordoba, Spain, Cordoba, Spain, ¹¹Department of Medicine, Hospital Universitario Reina Sofia, University of Cordoba, IMIBIC, Cordoba, Spain
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous inflammatory disease requiring individualized treatment strategies. Early identification of patients likely to respond to therapy is essential to…
Abstract Number: 2351 • ACR Convergence 2025
Modulation of Tyrosine Kinase 2- and Disease-Related Biomarkers by Zasocitinib (TAK-279), an Oral, Allosteric, Highly Selective and Potent Tyrosine Kinase 2 Inhibitor, Is Associated With Clinical Response in Patients with Active Psoriatic Arthritis
Amit Choudhury¹, Jie Cheng², Feng Hong¹, Sachin Kumar¹, Jay Tang¹, Paresh Thakker¹, Banishree Saha¹, Vinayagam Arunachalam³, Ting Hong³, Elena Tomaselli Muensterman¹, Haakan Wennbo³ and Iain McInnes⁴, ¹Takeda Development Center Americas, Inc.,, Cambridge, MA, ²Takeda Development Center Americas, Inc., Cambridge, MA, ³Takeda Development Center Americas, Inc, Cambridge, MA, ⁴University of Glasgow, Glasgow, United Kingdom
Background/Purpose: There is a significant unmet need for clinically informative biomarkers of disease activity and therapeutic response in immune-mediated inflammatory diseases (IMIDs). Tyrosine kinase 2…
Abstract Number: 2309 • ACR Convergence 2025
Lifestyle behaviours and disease activity in patients with psoriatic arthritis: the Dutch south west psoriatic arthritis study
Batoul Hojeij¹, Ilja Tchetverikov², Marijn Vis¹, Marc R Kok³, Yvonne Goekoop-Ruiterman⁴, Jessica Bijsterbosch⁵, Paul Baudoin⁶, Reinhard Bos⁷, Jos H van der Kaap⁸, Petra Kok⁹, Lindy-Anne Korswagen¹⁰ and Jolanda J Luime¹, ¹Erasmus MC, Rotterdam, Netherlands, ²Albert Schweitzer Hospital, Dordrecht, Netherlands, ³Maasstad Hospital, Rotterdam, Netherlands, ⁴Haga Hospital, the Hague, Netherlands, ⁵Amphia Hospital, Breda, Netherlands, ⁶Reumazorg Zuid West Nederland, Roosendaal, Netherlands, ⁷Medisch Centrum Leeuwarden, Leeuwarden, Netherlands, ⁸Admiraal De Ruyter Hospital, Goes, Netherlands, ⁹Reinier de Graaf Hospital, Delft, Netherlands, ¹⁰Franciscus Gasthuis and Vlietland, Rotterdam, Netherlands
Background/Purpose: Comprehensive assessment of multiple lifestyle behaviours and disease activity outcomes in psoriatic arthritis (PsA) is scarce. We aim to investigate lifestyle behaviours in patients…
Abstract Number: 1715 • ACR Convergence 2025
Spondyloarthritis and Psoriatic Arthritis Patients Under Immunosuppressive Conventional and Biologic DMARDs: Favorable Disease Safety and Attenuated Immunogenicity Following Recombinant Herpes Zoster Vaccination
Carla Saad¹, Eduardo Borba², Fernanda Chaer³, Ana C Medeiros-Ribeiro¹, Sandra G Pasoto¹, Nadia Emi Aikawa⁴, Luisa Correia⁵, Percival Sampaio-Barros⁶, Julio Moraes⁷, Murillo Dorio¹, Claudia Goldenstein-Schainberg¹, Clovis Artur Silva⁸ and Eloisa Bonfa², ¹Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, Brazil, ²Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, São Paulo, Brazil, ³Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Santos, Brazil, ⁴Rheumatology Division and Pediatric Rheumatology Unit, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, São Paulo, Brazil, ⁵Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Sao Paulo, ⁶Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, São Paulo, Brazil, ⁷Rheumatology Division, Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, Sao Paulo, SP, Brazil, Jundiai, Brazil, ⁸University of São Paulo, São Paulo, São Paulo, Brazil
Background/Purpose: Psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA) patients are at increased risk for herpes zoster(HZ) due to impaired cell-mediated immunity associated with the underlying…
Abstract Number: 1453 • ACR Convergence 2025
Real-World Comparative Effectiveness of Upadacitinib in Psoriatic Arthritis: Evaluation of Switching to Upadacitinib Versus Tumor Necrosis Factor Inhibitors or Interleukin-17 Inhibitors After First-Line Tumor Necrosis Factor Inhibitors
Philip J. Mease¹, William Tillett², Xiaolan Ye³, Christopher Saffore⁴, Molly Edwards⁵, Isabel Truman⁵, Sophie Barlow⁶, Jayne Stigler⁷, Bhumik Parikh⁸ and Daniel Aletaha⁹, ¹Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ²Department of Life Sciences, Centre for Therapeutic Innovation, University of Bath, Bath, United Kingdom, ³AbbVie Inc., Mettawa, IL, ⁴AbbVie Inc., waukegan, IL, ⁵Adelphi Real World, Bollington, United Kingdom, ⁶AbbVie, North Chicago, IL, ⁷AbbVie, Round Lake, IL, ⁸AbbVie, Hillsborough Township, NJ, ⁹Medical University Vienna, Wien, Austria
Background/Purpose: The aim of this study was to compare the effectiveness of switching from a first-line TNFi to upadacitinib (UPA), an oral JAKi, versus cycling…
Abstract Number: 1413 • ACR Convergence 2025
Restless Legs Syndrome in Patients with Psoriatic Arthritis: Association with Inflammatory, Clinical Parameters, and Comorbidities
Esther Toledano¹, Carlos Villegas², Carolina Cristina Chacón³, Cristina Hidalgo Calleja³, Belén Miguel³, Laura Blanco³, Ana Turrión⁴, Olga Compán⁵, Manuel Martín⁴, Susana Gómez³ and Carlos Montilla³, ¹Rheumatology Service, San Carlos Clinical Hospital, Madrid, Spain, ²Faculty of Medicine, University of Salamanca, Salamanca, Spain, ³Rheumatology Service, University Hospital of Salamanca, Salamanca, Castilla y Leon, Spain, ⁴Rheumatology Service, University Hospital of Salamanca, Salamanca, Spain, ⁵Rheumatology Service, University Hospital of Salamanca, Carbajosa de la Sagrada, ³⁷¹⁹¹, Spain
Background/Purpose: Restless legs syndrome (RLS) is a chronic neurological disorder associated with brain iron metabolism. Although RLS has been linked to various immune-mediated inflammatory diseases,…
Abstract Number: 0590 • ACR Convergence 2025
Effect of Deucravacitinib Treatment on Disease Activity–Associated Plasma Biomarkers in Patients With Active Psoriatic Arthritis: Results From 2 Phase 3 Studies
Vinod Chandran¹, Oliver FitzGerald², Philip J. Mease³, Lihi Eder⁴, Jose Scher⁵, Christopher Ritchlin⁶, Dafna D. Gladman⁷, Walter P Maksymowych⁸, Coryandar Gilvary⁹, Aditi Basu Bal⁹, Eleni Vritzali¹⁰ and Jinqi Liu⁹, ¹Division of Rheumatology, Departments of Medicine and Laboratory Medicine and Pathobiology, University of Toronto, and Gladman Krembil Psoriatic Arthritis Research Program, Krembil Research Institute, University Health Network, Toronto, Canada, ²UCD, Dublin ⁶, Dublin, Ireland, ³Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ⁴University of Toronto, Toronto, ON, Canada, ⁵New York University School of Medicine, New York, NY, ⁶University of Rochester Medical Center, Canandaigua, NY, ⁷Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Division of Rheumatology, Toronto, ON, Canada, ⁸Department of Medicine, University of Alberta, Edmonton, AB, Canada, ⁹Bristol Myers Squibb, Princeton, NJ, ¹⁰Bristol Myers Squibb, Boudry, Switzerland
Background/Purpose: Understanding how treatments affect disease-relevant biomarker expression is essential for advancing targeted therapies. Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, has…
Abstract Number: 0557 • ACR Convergence 2025
Efficacy of Upadacitinib in Male and Female Patients with PsA: Results from the SELECT-PsA 1 and 2 Trials
Lihi Eder¹, Axel Hueber², Lucia Novelli³, Tianming Gao³, Jayne Stigler⁴, Zhiyuan Du³, Rodrigo García Salinas⁵, Grace Wright⁶ and Sofia Ramiro⁷, ¹University of Toronto, Toronto, ON, Canada, ²Klinikum Nuernberg, Nuernberg, Germany, ³AbbVie, North Chicago, IL, ⁴AbbVie, Round Lake, IL, ⁵Hospital Italiano La Plata, La Plata, Argentina, ⁶Grace C Wright MD PC, New York, NY, ⁷Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: Biologic sex can impact both clinical phenotype and therapeutic response in PsA.1–3 Previous studies have suggested that male patients (pts) may achieve better treatment…

« Previous Page
1
…
5
6
7
8
9
…
93
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].